Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Neuphoria Therapeutics Inc.
| Metric | Neuphoria Therapeutics Inc. NEUPHealthcare |
|---|---|
| Quality Score | 61 / 100 |
| Revenue (latest) | $16M |
| Net income (latest) | −$369,632 |
| Operating margin | −7.2% |
| Net margin | −2.4% |
| Return on equity | −1.9% |
| Return on assets | −1.3% |
| Return on capital (ROCE) | −4.6% |
| Debt / equity | 0.50× |
| Revenue growth (YoY) | — |
| Altman Z″ (distress) | -16.04 |
| Accruals / assets | −1.6% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.